Over a lifetime, 1 out of 7 men will receive a diagnosis of prostate cancer. Although most patients present with localized or indolent disease, there are still a big proportion of patients that will eventually progress to metastatic prostate cancer, for which no curative treatment currently ...
177Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer BACKGROUND: Despite significant progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years (including agents targeting androgen receptor signaling, chemotherap...
Lutetium-177 labelled PSMA ligands for the treatment of metastatic castrate-resistant prostate cancer 来自 ResearchGate 喜欢 0 阅读量: 32 作者: AJAT Braat,H Ahmadzadehfar 展开 摘要: The use of 68Ga-PSMA-HBED-CC PET/CT has increased immensely in the last year. Based on 68Ga-PSMA-...
(lutetium lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate -specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathway inhibition ...
Interested in receiving information about PLUVICTO? PLUVICTO®Pulse provides educational support and materials for those considering and starting on treatment. Sign Up Today mCRPC, metastatic castration-resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive....
Bertram Yuh, MD, MISM, MSHCPM, discussed how single-port robotic surgery has changed treatment paradigms for patients with prostate cancer. Read More FDA Clears NDA of Intravesical Mitomycin in Non–Muscle-Invasive Bladder Cancer Sabrina Serani ...
药物别名 177Lu-PSMA-617 药效学 Lutetium Lu 177 vipivotide tetraxetan is a radioligand that exerts cytotoxic effects on cancer cells. Tumor uptake value is 11.2%ID/g. In clinical trials of patients with metastatic castration-resistant prostate cancer, treatment with lutetium Lu 177 vipivotide te...
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Targeted Radioligand Therapy for Treatment of Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the...
Novartis announced today that the FDA approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane anti
Based on theoretical and preclinical results, terbium-161 may be a valid alternative to lutetium-177 and yttrium-90 in radionuclide therapies. The large low-energy electron emission from terbium-161 is a favorable feature in the treatment of disseminated disease, but its impact on the radiosensitiv...